Daclatasvir and reduced‐dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min

Daclatasvir and reduced‐dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min

ABSTRACT Aim Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology (Carlton, Vic.) Vic.), 2019-03, Vol.24 (3), p.316-321
Hauptverfasser: Goel, Amit, Bhadauria, Dharmendra S, Kaul, Anupma, Verma, Prashant, Mehrotra, Mayank, Gupta, Amit, Sharma, Raj K, Rai, Praveer, Aggarwal, Rakesh
Format: Artikel
Sprache:eng
Schlagworte:
Cirrhosis
end‐stage renal disease
Epidermal growth factor receptors
Genotypes
Glomerular filtration rate
hepacivirus
Hepatitis C
Immunosuppressive agents
Interferon
Kidney diseases
Liver cirrhosis
Patients
renal insufficiency
Ribavirin
Ribonucleic acid
RNA
viral hepatitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Aim Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR)
ISSN:1320-5358
1440-1797
DOI:10.1111/nep.13222